

UNICHEM LABORATORIES LIMITED

Unichem Bhavan
Prabhat Estate, Off S.V.Road,
Jogeshwari (West),
Mumbai - 400 102.
Tel. No: +91 (22) 66 888 333
Fax. No: +91 (22) 267 843 91/ 5198
CIN: L99999MH1962PLC012451

PRESS RELEASE

Mumbai, Tuesday July 25, 2017

Unichem Laboratories receives ANDA approval from USFDA for Losartan Potassium And Hydrochlorothiazide tablets USP

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Losartan Potassium and Hydrochlorothiazide tablets USP, 50mg/12.5 mg, 100mg/12.5mg, and 100 mg/25mg, which are therapeutically equivalent to Hyzaar Tablets 50mg/12.5 mg, 100mg/12.5mg, and 100 mg/25mg of Merck Sharp & Dohme Corporation.

Losartan Potassium and Hydrochlorothiazide is a combination of Losartan Potassium, an angiotensin II receptor blocker (ARB) and Hydrochlorothiazide, a diuretic indicated for treatment of hypertension (to lower blood pressure) and for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

The product will be commercialized from Unichem's Ghaziabad plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur/Roha API Plant(s).

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com

For more information please contact:

Ms. Neema Thakore
Ph: +91-22-66888 404
E-mail: neema.thakore@unichemlabs.com

Mr. Rakesh Parikh
Ph: +91-22-66888 414
E-mail: rparikh@unichemlabs.com

***Disclaimer:** This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.*

